CCN4 and idiopathic pulmonary fibrosis: Accordingly, as therapeutic strategies targeting WISP1 are currently at Phase 1 clinical trials, our results, for the first time, uncover the molecular signature of WISP1 profibrotic biology in a cell and disease-specific context, i.e., dermal vs. lung fibroblasts and between healthy vs. IPF-diseased states.